Success Stories: From NIW to EB1A: Dual Approval for Postdoctoral Associate in Molecular Medicine Research

Client’s Testimonial:

“I had a great experience working with Chen immigration attorneys. Their service was excellent at every step. Their response to my queries was very quick and helpful. Very thankful to them for my EB1 approval.”

On February 10^th, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Postdoctoral Associate in the Field of Molecular Medicine (Approval Notice).

General Field: Molecular Medicine

Position at the Time of Case Filing: Postdoctoral Associate

Country of Origin: India

State of Residence at the Time of Filing: California

Approval Notice Date: February 10^th, 2025

Processing Time: 10 months, 12 days (Premium Processing Requested)

Case Summary:

We are pleased to share the success story of an EB1A (Alien of Extraordinary Ability) approval granted to a molecular medicine researcher whose work focuses on developing innovative approaches to the treatment and management of osteoarthritis. This client had previously secured EB-2 NIW approval with the support of the North America Immigration Law Group (NAILG) and has now successfully obtained EB-1A classification based on her extraordinary scientific contributions.

The client is especially recognized for her groundbreaking research on polyphenols and their impact on osteoarthritis, with additional expertise in inflammation, plant-derived compounds, and immunopathology. Her studies have produced new insights into how bioactive compounds like imperatorin and butein can reduce inflammation and improve joint health, research that addresses one of the most widespread chronic conditions affecting aging populations globally.

Her research has not only broadened scientific understanding but has also influenced the direction of therapeutic innovation. She has published 12 peer-reviewed scientific articles, which have collectively been cited 745 times by researchers in at least 56 countries. These achievements place her in the top 1% of most highly cited authors publishing on immunopathology topics over the past 8 years.

Professional Recognition and Influence:

To further demonstrate her influence in the field, the client has conducted at least 52 peer reviews for scientific journals and serves on the editorial board of a respected publication, recognitions reserved for trusted experts with deep subject matter expertise.

Her work has been supported by prestigious funding bodies, including:

The National Center for Complementary and Integrative Health (NCCIH)
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
The National Institutes of Health (NIH)

In addition to her osteoarthritis research, she has also contributed to developing improved immunoassays for detecting antibodies to HBV surface antigens in patient samples, showcasing her versatility and translational impact in biomedical science.

A compelling expert testimonial submitted with the petition summarized the importance of her contributions:

“Her widely disseminated research is exceptional and harbors tangible implications in enhancing osteoarthritis management and improving the well-being of countless individuals, an area indispensable for societal health and longevity.”

Final Result:

This EB1A petition highlights both the client’s internationally recognized expertise and the national and global relevance of her research. NAILG was proud to support her through this process, having previously assisted her with a successful NIW petition. We are honored to play a continued role in her journey and look forward to her future contributions to science and public health.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.